Cite

    Hercogová, J. et al. (n.d.). AB0954 A randomised, double-blind trial comparing the efficacy, safety and immunogenicity of msb11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis. Annals of the rheumatic diseases. p. 1602. [Online].